Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
Portfolio Pulse from Vandana Singh
Sanofi SA is reportedly considering the acquisition of Mirati Therapeutics Inc, which could strengthen Sanofi's drug pipeline and reduce its reliance on asthma medicine Dupixent. This would also aid Mirati in commercializing Krazati and funding further studies. Mirati's Krazati received FDA accelerated approval in December, but European regulators issued a negative opinion. Meanwhile, FDA advisers concluded that data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's Lumakras. Analysts believe this could provide a positive boost to Krazati's launch and short-term adoption rate.
October 06, 2023 | 4:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's potential acquisition could aid Mirati in commercializing Krazati and funding further studies. Analysts have increased Mirati's target price.
The potential acquisition by Sanofi could provide Mirati with the necessary resources to commercialize Krazati and fund further studies. This, along with the increased target price by analysts, could potentially increase Mirati's stock value.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Sanofi's potential acquisition of Mirati Therapeutics could strengthen its drug pipeline and reduce its reliance on Dupixent.
The acquisition of Mirati Therapeutics would provide Sanofi with a new drug, Krazati, which could diversify its portfolio and reduce its reliance on Dupixent. This could potentially increase Sanofi's stock value.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
FDA advisers concluded that data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen's Lumakras.
The lack of endorsement from FDA advisers for Amgen's Lumakras due to unreliable data could potentially negatively impact Amgen's stock value.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60